Evidence map›Paper›PMID 31196984›Full record

ArticleScience (New York, N.Y.)2019

Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism.

Vayu Maini Rekdal, Elizabeth N Bess, Jordan E Bisanz, Peter J Turnbaugh, Emily P Balskus

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 416 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
416citing papers in PubMed, 5 pooled it
28.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

416 citing papers in PubMed, 5 syntheses or guidelines pooled it, 707 citations in OpenAlex.

  1. Efficacy and safety of fecal microbiota transplantation in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Gut microbes · 2026
    Article
  15. Article
  16. Review
  17. Review
  18. Pharmacomicrobiomics-driven targeted drug delivery for precision microbiome modulation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  19. Article
  20. Review

356 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Vayu Maini RekdalDepartment of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138, USA.ORCID 0000-0002-8699-8902
Elizabeth N BessDepartment of Microbiology and Immunology, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA.ORCID 0000-0003-0349-0423
Jordan E BisanzDepartment of Microbiology and Immunology, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA.ORCID 0000-0002-8649-1706
Peter J TurnbaughDepartment of Microbiology and Immunology, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA. balskus@chemistry.harvard.edu peter.turnbaugh@ucsf.edu.ORCID 0000-0002-0888-2875
Emily P BalskusDepartment of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138, USA. balskus@chemistry.harvard.edu peter.turnbaugh@ucsf.edu.ORCID 0000-0001-5985-5714
University of California, San Francisco · USHarvard University · US

Funding

Training in Molecular, Cellular, and Chemical BiologyT32GM007598 · NIGMS · HARVARD UNIVERSITY · PI DULAC, CATHERINE · 1985 to 2019
$16.2M
Predicting and preventing drug metabolism by the human gut microbiomeR01HL122593 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2016 to 2026
$5.7M
Howard Hughes Medical InstituteNHLBI NIH HHS R01 HL122593NIGMS NIH HHS T32 GM007598
6 · The paper itself

Abstract

The human gut microbiota metabolizes the Parkinson's disease medication Levodopa (l-dopa), potentially reducing drug availability and causing side effects. However, the organisms, genes, and enzymes responsible for this activity in patients and their susceptibility to inhibition by host-targeted drugs are unknown. Here, we describe an interspecies pathway for gut bacterial l-dopa metabolism. Conversion of l-dopa to dopamine by a pyridoxal phosphate-dependent tyrosine decarboxylase from

Indexed as

Gastrointestinal MicrobiomeActinobacteriaAnimalsAntiparkinson AgentsBacterial ProteinsDecarboxylationDopamineEnterococcus faecalisGenome, BacterialHeLa CellsHumansLevodopaMaleMetabolic Networks and PathwaysMice, Inbred BALB CTyrosine3-fluoro-alpha-fluoromethyltyrosineAntiparkinson AgentsBacterial ProteinsDopamineLevodopaTyrosineTyrosine Decarboxylase

Identifiers

PMID31196984
PMCPMC7745125
OpenAlexW2951517287

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.